Marine Natural Products and Signaling Pathways

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 7379

Special Issue Editors


E-Mail Website
Guest Editor
Key Laboratory of Structure-Based Drug Design & Discovery of Education, College of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China
Interests: marine natural products; antitumor; sponge; fungi; signaling pathway

E-Mail Website
Guest Editor
State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Interests: fungal secondary metabolites; marine natural products; drug discovery; genome mining; biosynthesis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Marine natural products, as the bioactive products of secondary metabolites, including enzymes, lipids, and heteropolysaccharides, have played a crucial role in the discovery of novel lead compounds. The characteristics of abundant water, high salinity, high pressure, low temperature, flow, and complexity in the marine environment make the structural configurations of marine natural products more diverse, unique, and novel. Marine natural products possess unique regulatory mechanisms for combating different diseases, including apoptosis, autophagy, the Hippo signaling pathway, Jak STAT and the mTOR signaling pathway.

This Special Issue mainly focuses on the relationship between various natural products derived from marine sources and disease-related signaling pathways. It encourages the contribution of studies addressing new pathways for known components, or the study of pathways for the disocvery of novel molecules. Research articles and reviews that combine the above conditions are welcome for submission.

Dr. Haifeng Wang
Dr. Ling Liu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine natural products
  • signaling pathways
  • active molecules
  • novel molecular skeleton
  • regulation mechanism
  • omics

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 3303 KiB  
Article
The Marine Natural Compound Dragmacidin D Selectively Induces Apoptosis in Triple-Negative Breast Cancer Spheroids
by Esther A. Guzmán, Tara A. Peterson and Amy E. Wright
Mar. Drugs 2023, 21(12), 642; https://doi.org/10.3390/md21120642 - 15 Dec 2023
Cited by 1 | Viewed by 1713
Abstract
Cancer cells grown in 3D spheroid cultures are considered more predictive for clinical efficacy. The marine natural product dragmacidin D induces apoptosis in MDA-MB-231 and MDA-MB-468 triple-negative breast cancer (TNBC) spheroids within 24 h of treatment while showing no cytotoxicity against the same [...] Read more.
Cancer cells grown in 3D spheroid cultures are considered more predictive for clinical efficacy. The marine natural product dragmacidin D induces apoptosis in MDA-MB-231 and MDA-MB-468 triple-negative breast cancer (TNBC) spheroids within 24 h of treatment while showing no cytotoxicity against the same cells grown in monolayers and treated for 72 h. The IC50 for cytotoxicity based on caspase 3/7 cleavage in the spheroid assay was 8 ± 1 µM in MDA-MB-231 cells and 16 ± 0.6 µM in MDA-MB-468 cells at 24 h. No cytotoxicity was seen at all in 2D, even at the highest concentration tested. Thus, the IC50 for cytotoxicity in the MTT assay (2D) in these cells was found to be >75 µM at 72 h. Dragmacidin D exhibited synergy when used in conjunction with paclitaxel, a current treatment for TNBC. Studies into the signaling changes using a reverse-phase protein array showed that treatment with dragmacidin D caused significant decreases in histones. Differential protein expression was used to hypothesize that its potential mechanism of action involves acting as a protein synthesis inhibitor or a ribonucleotide reductase inhibitor. Further testing is necessary to validate this hypothesis. Dragmacidin D also caused a slight decrease in an invasion assay in the MDA-MB-231 cells, although this failed to be statistically significant. Dragmacidin D shows intriguing selectivity for spheroids and has the potential to be a treatment option for triple-negative breast cancer, which merits further research into understanding this activity. Full article
(This article belongs to the Special Issue Marine Natural Products and Signaling Pathways)
Show Figures

Figure 1

Review

Jump to: Research

43 pages, 7157 KiB  
Review
Deep-Sea Sponges and Corals off the Western Coast of Florida—Intracellular Mechanisms of Action of Bioactive Compounds and Technological Advances Supporting the Drug Discovery Pipeline
by Mina Iskandar, Kira M. Ruiz-Houston, Steven D. Bracco, Sami R. Sharkasi, Cecilia L. Calabi Villarroel, Meghna N. Desai, Alexandra G. Gerges, Natalia A. Ortiz Lopez, Miguel Xiao Barbero, Amelia A. German, Vinoothna S. Moluguri, Selina M. Walker, Juliana Silva Higashi, Justin M. Palma, Daena Z. Medina, Miit Patel, Prachi Patel, Michaela Valentin, Angelica C. Diaz, Jonathan P. Karthaka, Atzin D. Santiago, Riley B. Skiles, Luis A. Romero Umana, Maxwell D. Ungrey, Anya Wojtkowiak, Domenica V. Howard, Remy Nurge, Katharine G. Woods and Meera Nanjundanadd Show full author list remove Hide full author list
Mar. Drugs 2023, 21(12), 615; https://doi.org/10.3390/md21120615 - 28 Nov 2023
Viewed by 5330
Abstract
The majority of natural products utilized to treat a diverse array of human conditions and diseases are derived from terrestrial sources. In recent years, marine ecosystems have proven to be a valuable resource of diverse natural products that are generated to defend and [...] Read more.
The majority of natural products utilized to treat a diverse array of human conditions and diseases are derived from terrestrial sources. In recent years, marine ecosystems have proven to be a valuable resource of diverse natural products that are generated to defend and support their growth. Such marine sources offer a large opportunity for the identification of novel compounds that may guide the future development of new drugs and therapies. Using the National Oceanic and Atmospheric Administration (NOAA) portal, we explore deep-sea coral and sponge species inhabiting a segment of the U.S. Exclusive Economic Zone, specifically off the western coast of Florida. This area spans ~100,000 km2, containing coral and sponge species at sea depths up to 3000 m. Utilizing PubMed, we uncovered current knowledge on and gaps across a subset of these sessile organisms with regards to their natural products and mechanisms of altering cytoskeleton, protein trafficking, and signaling pathways. Since the exploitation of such marine organisms could disrupt the marine ecosystem leading to supply issues that would limit the quantities of bioactive compounds, we surveyed methods and technological advances that are necessary for sustaining the drug discovery pipeline including in vitro aquaculture systems and preserving our natural ecological community in the future. Collectively, our efforts establish the foundation for supporting future research on the identification of marine-based natural products and their mechanism of action to develop novel drugs and therapies for improving treatment regimens of human conditions and diseases. Full article
(This article belongs to the Special Issue Marine Natural Products and Signaling Pathways)
Show Figures

Figure 1

Back to TopTop